Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Plain-language summary

Whereas neurotoxic Aβ is derived from amyloid precursor protein (APP) by β- and γ-secretase cleavage, APP processing along the non-amyloidogenic pathway results in the secretion of the large neurotrophic ectodomain APPsα. Together, these data suggest that brain delivery of CTα16 can reverse synaptic damage and enhance functional plasticity of the neuronal network and thus holds therapeutic potential for tauopathies in general and AD in particular. • AAV-iCTα16 mediated expression of the CTα16 peptide rescues spine density in APP/APLP2-deficient cDKO mice. • AAV-iCTα16 restores normal synaptic plasticity in APP/APLP2-deficient cDKO mice. • AAV-iCTα16 restores normal spine density in aged transgenic THY-Tau22 mice, an Alzheimer model with Tau pathology. • Blood brain barrier targeted CTα16 containing liposomes mediate efficient peptide uptake into the brain. • Liposomal delivery of CTα16 peptide restores normal spine density in THYTau22 mice.

What this study adds

Evidence grade: Low

This study used viral and liposomal delivery of a neurotrophic peptide called CTα16 to restore spine density and synaptic plasticity in mouse models of Alzheimer's-like pathology. These are animal results, so it is too early to say whether this approach treats or prevents Alzheimer's disease in people.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rehra, L., Erdinger, S., Wagner, L., Baltissen, D., Just, J., König, L., et al. (2025). Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.114374

Vancouver

Rehra L, Erdinger S, Wagner L, Baltissen D, Just J, König L, et al. Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.114374. PMID: 41187812.

BibTeX

@article{rehra2025-41187812,
  author  = {Rehra, Lena and Erdinger, Susanne and Wagner, Lelia and Baltissen, Danny and Just, Jennifer and König, Leo and Mühlberg, Eric and Eisenzapf, Tom and others},
  title   = {{Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease}},
  journal = {Journal of Controlled Release},
  year    = {2025},
  doi     = {10.1016/j.jconrel.2025.114374},
  pmid    = {41187812},
  url     = {https://doi.org/10.1016/j.jconrel.2025.114374}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study used viral and liposomal delivery of a neurotrophic peptide called CTα16 to restore spine density and synaptic plasticity in mouse models of Alzheimer's-like pathology. These are animal results, so it is too early to say whether this approach treats or prevents Alzheimer's disease in people.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Controlled Release)
Journal's citation record 3 / 4 Journal of Controlled Release: journal h-index 376 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 6 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.0 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 3.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Ulrike Müller: h-index 60 (OpenAlex, whole career)
Institution's track record 1 / 3 Heidelberg University: institution h-index 1,344 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41187812)
Free to read 2 / 2 Free to read
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk genes beyond APOE from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →